Ann: PIQ market update, page-17

Hi George,

I had noticed the same thing with Omics a few days ago, I actually sent an email to IR to seek clarification on what was going on.
I didn't post anything on here because I didn't want to spook holders, I am yet to hear back on my email and mostly likely wont.

I am not fussed about Dominican Republic, it's been a dismal failure ever since it was announced more than 19months ago.
The original intention form Richard was to use DR as a gateway into the US, given the advances we have made with the testing capabilities (IVD) I don't think DR is that important anymore. From ASX Ann 7/3/18 - DR Royalty fees was stated as $1.5M over 9years (~$166k pa) so it's not a big market for us.

Atturos website is not updated often but they do mention PromarkerD on their news page, see : http://atturos.com/proteomics-international-and-atturos-announcement/

Dublin University also rehashed the ASX announcement on their innovation news page: https://www.ucd.ie/innovation/news-and-events/latest-news-items/promarkerd-closer-to-launch-across-europe/name,464479,en.html

I think Atturous is still focusing on its OcProDx technology (Test that can detect spread of prostrate cancer).

As for Patia, it is strange they are have not promoted the test on their website. They appear to heavily promote their Diabetes Prevent product though..

It's tough to really know what's going on and I think it's good stay skeptical until we start seeing revenues coming in.
What keeps me invested here is the fact Jannsen trust our PromarkerD test so much so that they collaborated with us on the canagliflozin trial and would even consider us to be a potential Cdx.

Aruc6393 - I doubt it, PD has been a very tight ship so far though almost every boat in this ocean called the stock market has a few holes so if anything it's a good sign

Let's see what the quarterly looks like folks...

FYI to all ---
There was $175k collected in PD license fees last FY - this was a surprise to me as i didn't think we had actually confirmed receipts for PromarkerD tests? Unless they are statutory license fees charged to distributors? Either way, was good to see.




Source: 2018 Annual Report, page 53